Última actualización 6 de julio de 2026
Key finding
Treatment with IPE compared with placebo was associated with significant reductions in the primary composite endpoint (HR, 0.55 [95% CI, 0.38, 0.78]; P=0.0009).
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial demonstrated that Icosapent ethyl significantly reduced cardiovascular events compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial demonstrated that Icosapent ethyl significantly reduced cardiovascular events compared to placebo.
These findings are clinically significant as they suggest that Icosapent ethyl can effectively lower the risk of cardiovascular events, which is crucial for patients at high risk of heart disease. This could lead to improved treatment strategies and better health outcomes for individuals with cardiovascular risk factors.
The study may have limited generalizability due to specific population characteristics. Potential confounding factors were not fully accounted for. The long-term effects of Icosapent ethyl beyond the study period are unknown.
Published in
Publication details and source links for this paper.
Michael M, Deepak LB, Eliot AB, et al. Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. American Journal of Preventive Cardiology. 2026;25:101387. doi:10.1016/j.ajpc.2025.101387
Icosapent ethyl significantly reduced the primary composite endpoint (HR, 0.55; P=0.0009).
No significant difference was found in the placebo group for the primary composite endpoint (HR, 1.44; P=0.02).
Icosapent ethyl significantly reduced the key secondary composite endpoint (HR, 0.52; P=0.002).
An absolute risk reduction of 11.2% was observed with Icosapent ethyl.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Icosapent ethyl and Absolute cardiovascular risk reduction, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), Major adverse cardiovascular events, 5-point composite.
This study contributes evidence to
Primary intervention
Icosapent ethyl
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
3
Evidence pairs
47
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Core evidence
The primary outcomes reported in this study.
Icosapent ethyl → Absolute cardiovascular risk reduction
Icosapent ethyl → Absolute cardiovascular risk reduction
Icosapent ethyl → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Icosapent ethyl → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Icosapent ethyl → Major adverse cardiovascular events, 5-point composite
Icosapent ethyl → Major adverse cardiovascular events, 5-point composite
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Icosapent ethyl and Absolute cardiovascular risk reduction, Icosapent ethyl and Cardiovascular Outcomes.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Absolute cardiovascular risk reduction
Measures Absolute cardiovascular risk reduction as a key outcome.
All studies measuring Cardiovascular Outcomes
Measures Cardiovascular Outcomes as a key outcome.
All studies on Icosapent ethyl
Contributes to Icosapent ethyl evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Icosapent ethyl appears to improve Absolute cardiovascular risk reduction.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Absolute cardiovascular risk reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Icosapent ethyl appears to improve Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Icosapent ethyl appears to improve Major adverse cardiovascular events, 5-point composite.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Major adverse cardiovascular events, 5-point composite
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
